Ubiquitin and PROTACs: Mechanism, Research Assays and Reagent Selection

Ubiquitin and PROTACs work together to remove selected intracellular proteins instead of simply blocking their activity. A PROTAC brings a protein of interest into proximity with an E3 ubiquitin ligase, promotes target ubiquitination and directs the tagged protein toward proteasomal degradation. For research teams, the practical challenge is not only choosing a degrader, it is building an assay with the correct target construct, E3-ligase system, ubiquitination components and cellular controls. Planning a targeted protein degradation study? Start with the featured recombinant proteins below, browse recombinant protein options, or submit your project for technical evaluation.

Quick Answer: Which Reagents Does a PROTAC Study Need?

The required reagents depend on the experimental question:

Recommended buying route: purchase a documented recombinant protein when its species, sequence boundaries and tag fit the planned assay. If the project needs a specialized domain, mutation, label, tag position or multi-protein ligase complex, request a feasibility assessment before planning around that format.

What Is the Ubiquitin Proteasome System?

Ubiquitin is a small regulatory protein that can be covalently attached to other proteins. Ubiquitination is controlled by an enzyme cascade:

1. E1 ubiquitin-activating enzyme uses ATP to activate ubiquitin.
2. E2 ubiquitin-conjugating enzyme receives activated ubiquitin from E1.
3. E3 ubiquitin ligase recognizes a substrate and helps transfer ubiquitin to that substrate.
4. Repeated transfer can form a polyubiquitin signal.
5. An appropriately tagged substrate can be recognized, unfolded and degraded by the 26S proteasome.

E3 ligases provide much of the substrate-recognition specificity. This makes them attractive molecular handles for targeted protein degradation. The foundational biology of regulated ubiquitin-dependent proteolysis established that destruction can function as a precise form of cellular control rather than nonspecific protein disposal. Ubiquitination does not always mean proteasomal degradation. The outcome depends on factors such as the ubiquitin-chain topology, substrate context, ligase system and cellular machinery. For that reason, evidence of target ubiquitination should be paired with direct measurement of target loss and mechanism controls.

What Is a PROTAC?

A proteolysis-targeting chimera, or PROTAC, is usually a heterobifunctional molecule with three functional parts:

• a ligand that binds the protein of interest;
• a ligand that recruits an E3 ubiquitin ligase; and
• a linker connecting the two ligands.

The first PROTAC concept used a chimeric molecule to recruit a target to an SCF ubiquitin-ligase complex. Later small-molecule systems demonstrated efficient target degradation using commonly recruited ligases such as VHL and CRBN. Representative studies showed catalytic protein knockdown with VHL-recruiting degraders and efficient CRBN-dependent degradation of BRD4.

How PROTAC-mediated degradation works

1. The target-binding end engages the protein of interest.
2. The ligase-binding end recruits an E3-ligase system.
3. A target–PROTAC–ligase ternary complex forms.
4. The E3 machinery positions the target for ubiquitin transfer.
5. The ubiquitinated target is processed by the proteasome.
6. The PROTAC may dissociate and participate in another degradation cycle.

This event-driven mechanism differs from occupancy-driven inhibition. A conventional inhibitor generally needs sufficient and sustained target occupancy to suppress activity. A degrader aims to trigger removal of the target protein, potentially affecting catalytic, scaffolding and regulatory functions together.

PROTACs vs Conventional Targeted Inhibitors

PROTAC activity cannot be predicted from binary affinity alone. A highly affine target ligand can still produce weak degradation if the linker or ligase orientation does not create a productive ternary complex. Conversely, favorable protein–protein contacts within the ternary complex can improve selectivity and degradation. Structural work has shown how cooperative recognition and new molecular contacts can determine PROTAC performance.

Why E3 Ligase Selection Matters

The E3-ligase recruiter influences which cells may respond, how the ternary complex is oriented and which resistance mechanisms may arise. CRBN and VHL are widely used in research, while MDM2, cIAP and an expanding group of other ligases provide alternative recruitment strategies.

CRBN-based PROTAC research

CRBN is a substrate-recognition component of the CRL4–CRBN E3-ligase complex. CRBN-recruiting degraders often use ligands derived from immunomodulatory imide chemistry. Before choosing this route, confirm CRBN expression in the cellular model and distinguish CRBN-dependent target degradation from changes produced by the ligase ligand itself.

VHL-based PROTAC research

VHL functions within a complex that includes Elongin B, Elongin C, CUL2 and RBX1. VHL-recruiting PROTACs are widely used for biochemical and cellular degradation studies. Construct boundaries and complex assembly matter: isolated VHL protein is not automatically equivalent to a functional VHL E3-ligase complex.

MDM2 and alternative ligases

MDM2 is both a p53-binding regulator and a RING-type E3 ligase. It can support targeted-degradation concepts, but assay design must match the relevant binding domain and ligase function. Beta LifeScience’s MDM2 protein selection guide provides domain and assay context, while the p53 protein guide can help plan MDM2–p53 studies. Important selection principle: a ligase receptor, a ligand-binding domain and a complete active E3 complex are different reagents. State which one the assay requires before ordering.

Featured Recombinant Proteins for PROTAC Research

The following catalog proteins can support specific parts of ubiquitin and targeted-degradation research. Suitability depends on the exact assay; none should be treated as a complete PROTAC assay kit.

These products can support selected component or binding studies, subject to assay-fit review. UBE2D1 compatibility with the chosen E1/E3 system must be confirmed, and isolated CRBN or VHL should not be treated as a complete functional E3-ligase complex.

View Human Ubiquitin  · Request Technical Evaluation

Which Protein Route Fits Your Workflow?

Choose catalog proteins for defined component studies

Choose a catalog protein when its documented species, sequence range, expression system and tag match the planned component or binding study. Use the procurement checklist below for the final order review.

Request custom expression for specialized constructs

Use the project evaluation route to request a feasibility assessment when the project may require:

• a target mutation or resistance variant;
• a precise ligand-binding domain;
• an alternative tag, tag-free format or site-specific label;
• a mammalian or insect-cell expression system;
• a multi-protein complex;
• small-scale feasibility expression before scale-up; or
• coordinated target and ligase constructs for an assay panel.

Availability of these specialized formats is project-dependent and should be confirmed before the assay plan is finalized.

Browse target-focused protein collections

Kinases are common targets in degrader research. The Beta LifeScience kinase protein collection can help teams compare species, mutations, domains, expression systems and tag formats. Select the exact construct against the target-binding warhead and planned assay rather than buying only by gene name.

Building a Reliable PROTAC Assay Cascade

Stage 1: Confirm binary binding

Measure whether the target ligand engages the protein of interest and whether the E3-ligase ligand engages its receptor or complex. Binary assays are useful for rejecting non-binding compounds, but they do not establish productive degradation. Use the procurement checklist below to confirm construct boundaries, tag position, activity evidence and buffer compatibility. Also test whether the chosen immobilization strategy changes access to the binding surface.

Stage 2: Measure ternary-complex formation

Ternary-complex assays test the interaction that distinguishes a PROTAC from two independent ligands. Useful measurements may include ternary affinity, cooperativity, complex lifetime and concentration dependence. A concentration series is essential because excessive PROTAC can favor separate binary complexes rather than the productive ternary complex—the commonly described hook effect. Do not rank compounds from a single concentration.

Stage 3: Test ubiquitin transfer

A biochemical ubiquitination experiment may require ubiquitin, E1, E2, the appropriate E3 complex, ATP/Mg²⁺, the target and the PROTAC. The exact E2 and E3 composition must be compatible. A purified ligase receptor without its required complex partners may bind a degrader while failing to support ubiquitin transfer.

Recommended controls include:

• reaction without PROTAC;
• target ligand and E3 ligand tested separately;
• reaction lacking ATP, E1, E2 or E3;
• non-binding or inactive degrader control;
• target-only and ligase-only controls; and
• detection of target-specific ubiquitination rather than total ubiquitin signal alone.

Stage 4: Confirm cellular target degradation

Measure both concentration and time dependence. Common performance parameters include:

• DC50: the concentration at which 50% target degradation is observed under specified experimental conditions;
• Dmax: maximum target depletion achieved in that experiment;
• onset and duration of degradation;
• recovery after compound washout; and
• downstream pathway or phenotypic response.

DC50 and Dmax depend on the cell line, treatment time, assay method and target baseline. They should not be treated as universal compound constants. If the reported DC50 is instead the half-maximal fitted response between the untreated baseline and the fitted Dmax, state the normalization method and curve model explicitly.

Stage 5: Demonstrate mechanism

Mechanism controls help distinguish PROTAC-mediated degradation from transcriptional suppression, toxicity or nonspecific protein loss. Depending on the system, use:

• proteasome inhibition rescue;
• E1 or cullin-pathway perturbation;
• competition with the free target or ligase ligand;
• a non-binding PROTAC epimer or linker control;
• CRBN-, VHL- or other ligase-deficient models;
• target mRNA measurement; and
• orthogonal target-protein detection.

What to Check Before Ordering Recombinant Proteins

Use one procurement checklist across the target, ligase and ubiquitination components:

• Identity: species, UniProt accession and mutation status
• Sequence: full length, domain or fragment boundaries
• Expression system: bacterial, insect, yeast or mammalian
• Tag: type, position and whether removal is available
• Activity: assay used, result and lot-specific evidence
• Purity: method and numerical specification
• Complex state: isolated subunit, receptor complex or complete functional ligase assembly
• Formulation: salt, glycerol, reducing agents and additives that could affect the assay
• Quantity: pilot screening, optimization, replicates and confirmatory work
• Documentation: COA, SDS-PAGE, sequence confirmation and activity data
• Format: liquid or lyophilized, storage requirements and freeze–thaw plan
• Commercial details: current price, pack size, availability and lead time

For a quote, provide the target name, species, construct boundaries, mutation, preferred tag, assay platform, required quantity and need for activity testing. This allows the technical team to evaluate whether a catalog protein or custom construct is the better route.

Common Reasons a PROTAC Experiment Underperforms

Applications in Targeted Therapy Research

Oncology

PROTAC research has explored degradation of hormone receptors, BET proteins, kinases and other cancer-associated targets. The modality is attractive when removal of a protein may provide a different biological outcome from active-site inhibition. CRBN- and VHL-recruiting degraders helped establish the feasibility of small-molecule targeted degradation in cellular and in vivo models.

Drug-resistance research

Degraders can be evaluated against targets carrying resistance mutations or elevated expression. This does not guarantee that a PROTAC will overcome resistance: changes in target binding, ligase expression, ubiquitination machinery, transport or proteasome function can also reduce degradation.

Chemical biology and target validation

PROTACs can provide rapid, reversible chemical depletion without permanently editing the genome. Comparing degradation with inhibition can help researchers separate catalytic activity from scaffolding or regulatory functions.

Expansion beyond oncology

Targeted protein degradation is being investigated in areas including inflammation, immune regulation, neurobiology and infectious-disease research. Tissue exposure, ligase availability, safety and target biology remain central development questions. The field’s opportunities and limitations are reviewed in detail by Békés and colleagues and by He and colleagues (Békés et al., 2022; He et al., 2022).

Why Plan the Protein Panel With Beta LifeScience?

Beta LifeScience provides recombinant proteins across multiple expression systems and offers custom protein expression and purification. For PROTAC research, this creates two practical purchasing routes:

1. Catalog route: select documented target, E2 or E3-related proteins for initial binding and assay-development work.
2. Feasibility route: request an assessment for a project-specific domain, mutation, tag, label, expression host or protein complex when the catalog format does not match the assay. Specialized formats should be treated as proposed requirements until Beta LifeScience confirms feasibility.

The strongest inquiry describes the complete experimental system rather than requesting one protein in isolation. Include the protein of interest, E3-ligase route, intended assay, construct boundaries, tag requirements, quantity and required QC. This helps identify where existing catalog proteins fit and where custom production may be necessary. Research-use note: The linked proteins are research-use-only reagents. They are not therapeutic products, PROTAC compounds or complete functional degradation kits. Confirm assay-specific activity, required ligase partners and current commercial details before ordering.

Explore Recombinant Proteins · Discuss Custom Protein Expression · Submit Your Project

Frequently Asked Questions

Is ubiquitin itself a PROTAC?

No. Ubiquitin is the regulatory protein attached to substrates during ubiquitination. A PROTAC is a designed molecule that recruits a target protein and an E3 ligase to promote target ubiquitination and degradation.

Are CRBN and VHL complete E3 ligases?

No. They are substrate-recognition components operating within larger ligase assemblies. An isolated CRBN or VHL protein may support selected binding studies, but functional ubiquitination can require the relevant multi-protein complex.

Can a PROTAC degrade any protein?

Not automatically. The target needs a suitable ligand, the compound must reach the relevant cellular compartment, an appropriate ligase must be present, and the ternary complex must orient the target productively for ubiquitination and degradation.

What is the best first assay for a new PROTAC?

Start with confirmed binary binding, then measure ternary-complex formation and cellular target degradation. Add ubiquitination and mechanism controls to establish how the observed target loss occurs.

Does the lowest DC50 identify the best candidate?

Not by itself. Compare DC50 with Dmax, kinetics, selectivity, recovery after washout, cell viability, pathway response and exposure. Use the same cell model, treatment time and detection method for fair ranking.

Should I buy full-length protein or a domain?

Choose the construct that preserves the ligand-binding surface and supports the assay. A domain can improve solubility and simplify biophysical analysis, while full-length protein may retain additional interfaces or conformational context. Confirm boundaries before ordering.

Conclusion

Ubiquitin supplies the cellular tagging system, while PROTACs redirect that system toward a selected protein. A successful targeted-degradation project therefore depends on more than compound design: it requires a compatible target construct, the correct E3-ligase context, suitable ubiquitination components and mechanism-focused controls. Define the assay stage first, then select proteins by species, sequence, activity, tag, complex state and formulation. To source catalog components or discuss a project-specific construct, submit a Beta LifeScience technical evaluation request.

Scientific References

1. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. The EMBO Journal. 1998;17(24):7151–7160. doi:10.1093/emboj/17.24.7151. PMID: 9839944.
2. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences USA. 2001;98(15):8554–8559. doi:10.1073/pnas.141230798. PMID: 11438690.
3. Bondeson DP, Mares A, Smith IED, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology. 2015;11(8):611–617. doi:10.1038/nchembio.1858. PMID: 26075522.
4. Lu J, Qian Y, Altieri M, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chemistry & Biology. 2015;22(6):755–763. doi:10.1016/j.chembiol.2015.05.009. PMID: 26051217.
5. Winter GE, Buckley DL, Paulk J, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348(6241):1376–1381. doi:10.1126/science.aab1433. PMID: 25999370.
6. Gadd MS, Testa A, Lucas X, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nature Chemical Biology. 2017;13(5):514–521. doi:10.1038/nchembio.2329. PMID: 28288108.
7. Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery. 2022;21(3):181–200. doi:10.1038/s41573-021-00371-6. PMID: 35042991.
8. He M, Cao C, Ni Z, et al. PROTACs: great opportunities for academia and industry—an update from 2020 to 2021. Signal Transduction and Targeted Therapy. 2022;7:181. doi:10.1038/s41392-022-00999-9. PMID: 35680848.